Madrigal director granted stock and options

Madrigal Pharmaceuticals director James M. Daly reported awards of company equity as part of his compensation.

Rhea-AI Filing Summary

Madrigal Pharmaceuticals director James M. Daly reported awards of company equity as part of his compensation. He received 454 restricted stock units, which represent an equivalent number of common shares when they vest. He was also granted a stock option for 766 shares of common stock at an exercise price of $499.86 per share.

Both the restricted stock units and the option vest 100% on the earlier of June 17, 2027 or the date of Madrigal’s 2027 annual meeting of stockholders, as long as he continues in service with the company. Following the grant, Daly directly holds 3,081 shares of common stock and the newly granted option on 766 shares.

Insider Trade Summary

Grant/Award: 1,220 shares

Grant/Award 2 txns

Insider Daly James M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	766	$0.00	$0.00
Grant/Award	Common Stock	454	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 766 contracts (Direct); Common Stock — 3,081 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
2. F2. The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Key Figures

Restricted stock units granted: 454 units Stock options granted: 766 options Option exercise price: $499.86 per share +4 more

7 metrics

Restricted stock units granted 454 units Director equity award on June 17, 2026

Stock options granted 766 options Director equity award on June 17, 2026

Option exercise price $499.86 per share Stock Option (Right to Buy) grant

Common shares held after grant 3,081 shares Direct ownership following June 17, 2026 awards

Underlying shares for option 766 shares Common stock underlying the new option

Option expiration date June 17, 2036 End of term for 766-share option

Vesting date trigger June 17, 2027 Earlier of this date or 2027 annual meeting

Key Terms

restricted stock units, Stock Option (Right to Buy), vests as to 100% of underlying shares, annual meeting of stockholders

4 terms

restricted stock units financial

"Represents a grant of restricted stock units which vest on the earlier of"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with underlying security title Common Stock"

vests as to 100% of underlying shares financial

"The option vests as to 100% of underlying shares on the earlier of"

annual meeting of stockholders financial

"the date of the Issuer's annual meeting of stockholders to be held in 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Madrigal Pharmaceuticals (MDGL) director James M. Daly receive?

James M. Daly received 454 restricted stock units and a stock option for 766 shares of Madrigal common stock. These awards form part of his director compensation and were granted at an exercise price of $499.86 per share for the option.

When do James M. Daly’s new Madrigal (MDGL) equity awards vest?

Both the 454 restricted stock units and the option for 766 shares vest 100% on the earlier of June 17, 2027 or Madrigal’s 2027 annual stockholder meeting, provided Daly continues in service with the company through that vesting date.

What is the exercise price and term of James M. Daly’s new Madrigal (MDGL) stock option?

The newly granted stock option covers 766 shares of Madrigal common stock at an exercise price of $499.86 per share. The option expires on June 17, 2036, giving Daly a long-dated right to purchase shares once vesting conditions are met.

How many Madrigal (MDGL) shares does James M. Daly hold after this Form 4 transaction?

After these awards, Daly directly holds 3,081 shares of Madrigal common stock, according to the filing. He also holds a newly granted option to acquire 766 additional shares, subject to vesting and payment of the $499.86 per-share exercise price.

Are James M. Daly’s Madrigal (MDGL) awards tied to continued service?

Yes. Both the 454 restricted stock units and the option for 766 shares vest only if Daly continues in service with Madrigal through the earlier of June 17, 2027 or the date of the company’s 2027 annual meeting of stockholders, as disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly James M

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 400

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A(1)		454	A	$0	3,081	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$499.86	06/17/2026		A		766		(2)	06/17/2036	Common Stock	766	$0	766	D

Explanation of Responses:

1. Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

2. The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)